Acumen Pharmaceuticals Stock Working Capital
| ABOS Stock | USD 3.18 0.02 0.63% |
Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 233.6 M | 141.6 M | |
| Change In Working Capital | 3.9 M | 2 M | |
| Working Capital | 0.00 | 0.00 |
Acumen | Working Capital |
Acumen Pharmaceuticals Company Working Capital Analysis
Acumen Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Acumen Pharmaceuticals Working Capital | 233.64 M |
Most of Acumen Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acumen Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Working Capital. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Acumen Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Acumen Pharmaceuticals has a Working Capital of 233.64 M. This is 45.11% lower than that of the Biotechnology sector and 56.62% lower than that of the Health Care industry. The working capital for all United States stocks is 84.19% higher than that of the company.
Acumen Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in working capital category among related companies.
Acumen Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (22.62 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 9.12 % | ||||
| Shares Owned By Institutions | 72.66 % | ||||
| Number Of Shares Shorted | 1.24 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) | ||||
| EBITDA | (60.95 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 31.05 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 4.61 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Short Ratio | 2.78 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 12.8 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.082 | ||||
| Market Capitalization | 189.85 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
| Net Asset | 310.12 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acumen Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acumen Pharmaceuticals' short interest history, or implied volatility extrapolated from Acumen Pharmaceuticals options trading.
Pair Trading with Acumen Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acumen Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acumen Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Acumen Stock
| 0.8 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.73 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.8 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Acumen Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acumen Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acumen Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acumen Pharmaceuticals to buy it.
The correlation of Acumen Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acumen Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acumen Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acumen Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Acumen Pharmaceuticals Piotroski F Score and Acumen Pharmaceuticals Altman Z Score analysis. For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Acumen Stock analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 0.033 | Return On Assets (0.15) | Return On Equity (0.23) |
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acumen Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.